These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27458622)

  • 21. Pharmacogenetics in the rheumatic diseases.
    Cronstein BN
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):16-9. PubMed ID: 17121484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0.
    Ventura-Ríos L; Bañuelos-Ramírez D; Hernández-Quiroz Mdel C; Robles-San Román M; Irazoque-Palazuelos F; Goycochea-Robles MV
    Reumatol Clin; 2012; 8(4):189-94. PubMed ID: 22673388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous bone marrow transplantation versus alternative drugs in pediatric rheumatic diseases.
    Lepore L; Kiren V
    Haematologica; 2000 Nov; 85(11 Suppl):89-92. PubMed ID: 11268332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of malignancy associated with biologic agents in pediatric rheumatic disease.
    Mannion ML; Beukelman T
    Curr Opin Rheumatol; 2014 Sep; 26(5):538-42. PubMed ID: 25010437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interstitial lung disease and connective tissue diseases].
    Guler S; Geiser T
    Ther Umsch; 2016; 73(1):37-42. PubMed ID: 26884219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelial progenitor cells and rheumatic disease modifying therapy.
    Lo Gullo A; Aragona CO; Scuruchi M; Versace AG; Saitta A; Imbalzano E; Loddo S; Campo GM; Mandraffino G
    Vascul Pharmacol; 2018 Sep; 108():8-14. PubMed ID: 29842927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
    Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease-modifying antirheumatic drugs.
    Belavic J
    Nursing; 2010 Nov; 40(11):20. PubMed ID: 20975424
    [No Abstract]   [Full Text] [Related]  

  • 29. Putative effects of potentially anti-angiogenic drugs in rheumatic diseases.
    Maruotti N; Cantatore FP; Ribatti D
    Eur J Clin Pharmacol; 2014 Feb; 70(2):135-40. PubMed ID: 24196651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.
    Alten R; Maleitzke T
    Ann Med; 2013 Jun; 45(4):357-63. PubMed ID: 23650978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy of dyslipidemia in rheumatic diseases].
    Vordenbäumen S; Schinner S; Halle M; Fischer-Betz R; Schneider M
    Z Rheumatol; 2010 Oct; 69(8):689-92, 694-5. PubMed ID: 20862479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.
    Miyabe Y; Lian J; Miyabe C; Luster AD
    Nat Rev Rheumatol; 2019 Dec; 15(12):731-746. PubMed ID: 31705045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Institute of Rheumatology and progress of antirheumatic therapy].
    Sigidin IaA
    Vestn Ross Akad Med Nauk; 1998; (12):7-9. PubMed ID: 9987950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-cytokine antibodies for rheumatic diseases.
    Atzeni F; Sarzi-Puttini P
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fetal safety profile of drugs used in the treatment of inflammatory rheumatic diseases].
    Falcão S; Mourão AF; Pimentão JB; Branco JC
    Acta Reumatol Port; 2007; 32(4):323-31. PubMed ID: 18159198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to EULAR's recommendations on comorbidity management minimizes the discontinuation of bDMARDS for intolerance in patients with chronic inflammatory rheumatic diseases.
    Reyes-Rivet L; Bellier A; Baillet A; Pham T; Gaudin P; Allenet B; Gastaldi R
    Joint Bone Spine; 2021 Dec; 88(6):105234. PubMed ID: 34098103
    [No Abstract]   [Full Text] [Related]  

  • 38. [Infections during antirheumatic treatment].
    Kneitz C
    Dtsch Med Wochenschr; 2014 Aug; 139(31-32):1593-5. PubMed ID: 25076314
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanisms of action of methotrexate.
    Chan ES; Cronstein BN
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S5-8. PubMed ID: 24219035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infections and treatment of patients with rheumatic diseases.
    Atzeni F; Bendtzen K; Bobbio-Pallavicini F; Conti F; Cutolo M; Montecucco C; Sulli A; Valesini G; Sarzi-Puttini P
    Clin Exp Rheumatol; 2008; 26(1 Suppl 48):S67-73. PubMed ID: 18570757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.